EID2

Across TCGA pan-cancer cohorts, EID2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EID2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EID2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EID2 expression acts as an unfavorable survival marker.

LUAD, CCRCC, and GBM are the cancer types where EID2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.766	1.000	.006	26	view →
CCRCC	OS	Median	All	0.535	1.000	.030	18	view →
GBM	DFS	Tertile	All	0.369	0.947	<.001	15	view →
LSCC	DFS	Quartile	All	0.187	1.000	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EID2–LUAD (DFS)

Open the LUAD breakdown →